Antibodies Produced by CLL Phenotype B Cells in Patients With Myasthenia Gravis Are Not Directed Against Neuromuscular Endplates - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36754834/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusions: Our study suggests that AChR autoantibodies are produced by nonmalignant, polyclonal B cells The new anti-CD20 treatment obinutuzumab might be considered in effectively treating AChR MG.
Complement Activation Profiles in Anti-AChR Positive Myasthenia Gravis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36752022/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusions: Markers indicative of complement activation are prominently increased in patients with AChR-Ab MG despite standard immunosuppressive therapies. Complement inhibition proximal to C5 cleavage should be explored for its potential therapeutic benefits in AChR-Ab MG.
Myasthenia gravis: Frequently asked questions
Source : https://www.ccjm.org/content/90/2/103
Myasthenia gravis is a disorder of neuromuscular junction transmission, the result of antibodies against the post-synaptic aspect of the neuromuscular junction. Its clinical hallmark is fatigable weakness of skeletal muscles,...
Conclusions: This review uses a question-and-answer format to provide up-to-date, high-yield, clinically relevant information on myasthenia gravis.
Kearns-Sayre Syndrome Masquerading as Myasthenia Gravis : Retinal Cases and Brief Reports
sthenia gravis (MG). Methods: Case report. Results: A 15-year-old male with a presumed diagnosis of MG presented with blurry vision, ophthalmoplegia, and ptosis. He was found to have a mitochondrial...
Conclusions: We report a case of KSS found to have a novel large-scale mtDNA deletion. The presence of a mitochondrial pigmentary retinopathy found on dilated examination led to reconsideration of the previous diagnosis of MG and ultimately led to the correct diagnosis of KSS.
What are the treatment options for myasthenia gravis if first-line agents fail?
Source : https://www.ccjm.org/content/90/2/81
If the patient with myasthenia gravis (MG) has been taking adequate doses of a first-line medication, typically pyridostigmine, for a sufficient duration but without significant efficacy, or has experienced substantial...
Conclusions: If the patient with myasthenia gravis (MG) has been taking adequate doses of a first-line medication, typically pyridostigmine, for a sufficient duration but without significant efficacy, or has experienced substantial adverse effects, it may be time to consider immunosuppressive therapy. In 5% to 20% of patients, there may be...